TABLE 5.
Top 30 most significantly altered canonical cardiac pathways in embryonic cardiomyocytes after DNMT3a siRNA treatment
| Pathway | −log(P) | Ratio (%)a | Activation z score |
|---|---|---|---|
| Calcium signaling | 9.15 | 17.4 | −0.258 |
| Actin cytoskeleton signaling | 6.53 | 13.8 | 1.800 |
| Role of NFAT in cardiac hypertrophy | 5.63 | 14.0 | −0.600 |
| PKA signaling | 5.53 | 10.6 | −0.898 |
| Cardiac hypertrophy signaling | 4.85 | 12.1 | 0.000 |
| G-protein coupled receptor signaling | 4.6 | 11.3 | - |
| Integrin signaling | 4.28 | 11.9 | 0.000 |
| Inhibition of matrix metalloproteases | 4.05 | 23.1 | — |
| Epithelial adherens junction signaling | 4.01 | 13.0 | — |
| PAK signaling | 3.98 | 15.7 | 0.277 |
| Factors promoting cardiogenesis in vertebrates | 3.82 | 15.2 | — |
| SAPK/JNK signaling | 3.72 | 14.9 | −0.535 |
| Renin-angiotensin signaling | 3.55 | 13.8 | −1.941 |
| Endothelin-1 signaling | 3.51 | 11.6 | −1.500 |
| Tight junction signaling | 3.25 | 11.4 | NaN |
| Cardiac β-adrenergic signaling | 3.09 | 12.0 | −0.905 |
| Insulin receptor signaling | 3.05 | 11.9 | −0.775 |
| Dopamine-DARPP32 feedback in cAMP signaling | 3.02 | 11.2 | −2.183 |
| NO | 2.93 | 10.0 | 1.342 |
| NO signaling in the cardiovascular system | 2.92 | 13.0 | −0.577 |
| ERK/MAPK signaling | 2.66 | 10.2 | −1.606 |
| Cardiomyocyte differentiation via BMP receptors | 2.63 | 25.0 | 2.000 |
| IGF-1 signaling | 2.56 | 12.4 | −1.414 |
| Phospholipase C signaling | 2.50 | 9.28 | −0.577 |
| α-adrenergic signaling | 2.46 | 12.6 | 0.302 |
| Sphingosine-1-phosphate signaling | 2.14 | 11.0 | 0.905 |
| eNOS signaling | 2.00 | 9.86 | −0.333 |
| TGF-β signaling | 2.00 | 11.5 | −1.414 |
| STAT3 pathway | 1.58 | 11.0 | −1.414 |
| Embryonic stem cell differentiation into cardiac lineages | 1.08 | 20.0 | — |
a
Percentage of genes in the pathway that were changed in expression.